1. Iwatsuki K, Yamamoto T, Tsuji K, Suzuki D, Fujii K, Matsuura H, Oono T (2004) A spectrum of clinical manifestations caused by host immune responses against Epstein–Barr virus infections. Acta Med Okayama 58:169–180
2. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES (2009) Epstein–Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol 20:1472–1482
3. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO (1985) Evidence for active Epstein–Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 102:1–7
4. Chan JKC, Jaffe ES, Ralfkiaer E, Ko YH (2008) Aggressive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 276–277
5. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC (2008) Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 285–288